HCA Healthcare (NYSE:HCA) Given New $366.00 Price Target at Barclays

HCA Healthcare (NYSE:HCA - Free Report) had its target price cut by Barclays from $392.00 to $366.00 in a research report report published on Monday morning,Benzinga reports. They currently have an overweight rating on the stock.

Other equities research analysts have also issued research reports about the stock. Cantor Fitzgerald restated an "overweight" rating and issued a $392.00 target price on shares of HCA Healthcare in a report on Tuesday, October 1st. Morgan Stanley decreased their price objective on shares of HCA Healthcare from $406.00 to $355.00 and set an "equal weight" rating for the company in a research note on Tuesday, December 17th. TD Cowen decreased their price objective on shares of HCA Healthcare from $450.00 to $440.00 and set a "buy" rating for the company in a research note on Monday, October 28th. Raymond James lowered shares of HCA Healthcare from an "outperform" rating to a "market perform" rating in a research note on Friday, November 22nd. Finally, Truist Financial decreased their price objective on shares of HCA Healthcare from $430.00 to $390.00 and set a "buy" rating for the company in a research note on Monday, January 6th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, HCA Healthcare presently has a consensus rating of "Moderate Buy" and a consensus target price of $382.19.

HCA Healthcare Trading Up 6.1 %

Shares of HCA Healthcare stock traded up $19.11 during trading on Monday, hitting $332.18. The company's stock had a trading volume of 2,737,433 shares, compared to its average volume of 1,773,438. The company has a debt-to-equity ratio of 48.71, a current ratio of 1.12 and a quick ratio of 1.00. HCA Healthcare has a 52 week low of $281.61 and a 52 week high of $417.14. The stock has a market cap of $84.14 billion, a price-to-earnings ratio of 14.92, a price-to-earnings-growth ratio of 1.09 and a beta of 1.64. The stock has a 50-day moving average price of $313.49 and a two-hundred day moving average price of $353.13.

HCA Healthcare (NYSE:HCA - Get Free Report) last issued its quarterly earnings results on Friday, January 24th. The company reported $6.22 EPS for the quarter, beating analysts' consensus estimates of $6.03 by $0.19. HCA Healthcare had a net margin of 8.52% and a return on equity of 520.98%. During the same quarter in the previous year, the company earned $5.90 EPS. Equities research analysts anticipate that HCA Healthcare will post 21.75 EPS for the current fiscal year.

HCA Healthcare Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Stockholders of record on Monday, March 17th will be given a dividend of $0.72 per share. The ex-dividend date of this dividend is Monday, March 17th. This represents a $2.88 annualized dividend and a dividend yield of 0.87%. This is a boost from HCA Healthcare's previous quarterly dividend of $0.66. HCA Healthcare's dividend payout ratio (DPR) is 11.85%.

Insider Buying and Selling

In other HCA Healthcare news, insider Erol R. Akdamar sold 2,900 shares of HCA Healthcare stock in a transaction dated Thursday, November 14th. The shares were sold at an average price of $353.00, for a total value of $1,023,700.00. Following the completion of the transaction, the insider now directly owns 6,843 shares of the company's stock, valued at approximately $2,415,579. The trade was a 29.76 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Phillip G. Billington sold 3,897 shares of HCA Healthcare stock in a transaction dated Thursday, November 14th. The stock was sold at an average price of $350.00, for a total transaction of $1,363,950.00. Following the completion of the transaction, the senior vice president now directly owns 52,702 shares of the company's stock, valued at $18,445,700. This trade represents a 6.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Legacy Investment Solutions LLC bought a new position in shares of HCA Healthcare in the third quarter worth approximately $39,000. Capital Performance Advisors LLP bought a new position in shares of HCA Healthcare during the third quarter worth $41,000. Canoe Financial LP bought a new position in shares of HCA Healthcare during the third quarter worth $41,000. Northwest Investment Counselors LLC bought a new position in shares of HCA Healthcare during the third quarter worth $44,000. Finally, Friedenthal Financial bought a new position in shares of HCA Healthcare during the third quarter worth $50,000. 62.73% of the stock is owned by hedge funds and other institutional investors.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.